AA
VERA icon

AlphaCentric Advisors’s Vera Therapeutics VERA Stock Holding History

AlphaCentric Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,500
Closed -$332K – 282
2024
Q3 		$332K Buy
+7,500
New +$285K 0.25% 104

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

AlphaCentric Advisors's VERA Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Vera Therapeutics (VERA) in Q4 2024, closing a stake of 7,500 shares — an estimated $332K sold.

AlphaCentric Advisors first reported a position in VERA in Q3 2024 and held it in 1 quarter. The position peaked at $332K in Q3 2024. 178 funds tracked by Wall St. Rank hold VERA as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Vera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 7,500 Vera Therapeutics shares in Q4 2024, an estimated $332K.
  • AlphaCentric Advisors first reported a position in Vera Therapeutics in Q3 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's Vera Therapeutics position peaked at $332K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.